Pernix Therapeutics (PTX) Misses Q2 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pernix Therapeutics (PTX) PT Trimmed to $14 at Brean Capital Amid Weak Q2
August 7, 2015 8:57 AM EDTBrean Capital analyst Difei Yang lowered the price target on Pernix Therapeutics (NASDAQ: PTX) to $14.00 (from $17.00) following weak Q2, but maintianed a Buy rating.
Yang commented, "Q2 was a weak quarter for revenue and EPS. Management lowered guidance for a second... More
